P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Abstract : Bleomycin is an anti-cancer drug used to treat different malignancies, mainly lymphomas, germ cell tumors. Unfortunately, bleomycin has major, pulmonary toxicity that affects 20% of treated individuals with pulmonary fibrosis being the most devastating form. Deglyco-bleomycin is a molecule derived from bleomycin in which the sugar residue D-mannosyl-L-glucose disaccharide has been deleted. The objective of this study is to assess the anti-cancerous activity and the lung toxicity of deglyco-bleomycin. We compared in vivo the antitumor activity in three rodent models after intraperitoneal administrated deglyco-bleomycin and bleomycin. Pulmonary toxicity was in depth examined after intratracheal administration of both chemotherapeutic agents. We demonstrate in vivo in rodent cancer models, including a human Hodgkin lymphoma xenograft and a syngeneic melanoma model, that intra-peritoneal deglyco-bleomycin is as effective as bleomycin...
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01512940
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : lundi 24 avril 2017 - 13:47:08
Dernière modification le : vendredi 8 juin 2018 - 14:50:23

Lien texte intégral

Identifiants

Citation

Olivier Burgy, Guillaume Wettstein, Pierre-Simon Bellaye, Nathalie Decologne, Cindy Racoeur, et al.. P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. QJM: An International Journal of Medicine, Oxford University Press (OUP), 2016, 109 (suppl_1), pp.S58. 〈https://academic.oup.com/qjmed/article-abstract/109/suppl_1/S58/2565712/P105-Deglycosylated-bleomycin-has-the-antitumor?redirectedFrom=fulltext〉. 〈10.1093/qjmed/hcw120.006〉. 〈hal-01512940〉

Partager

Métriques

Consultations de la notice

74